Please assess the completion status of the following clinical trial:

Trial Title: Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Acute myeloid leukemia (AML) as defined by World Health Organization (WHO) criteria, any subtype, de novo or secondary, except acute promyelocytic leukemia (APL)~* One of the following:~  * Previously untreated, with adverse-risk cytogenetics, including any one of the following:~    * Complete or partial deletion of chromosome 7~   * Complete or partial deletion of chromosome 5~   * At least 3 numerical or structural abnormalities, other than t(15;17), t(8;21) or inv(16) or variant~   * 11q23 abnormalities~   * Inv(3) or variant such as t(3:3)~ * Previously untreated, transformed from prior myelodysplastic syndrome (MDS) or myeloproliferative disorder (MPD) other than CML~ * Persistent leukemia following one cycle of 3+7 induction therapy (cytarabine plus either daunorubicin or idarubicin), any cytogenetic risk group~* Left ventricular ejection fraction (LVEF) \> 50% based on multi gated acquisition scan (MUGA) scan or 2-dimensional (2-D) echocardiogram~* Serum creatinine =\< 1.5 x upper limit of normal (ULN)~* Serum bilirubin =\< 1.5 x ULN~* Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 x ULN~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky \>= 60%)~* Patients with high initial white blood cell (WBC) should have the WBC reduced to below 50 x 10\^9/L with hydroxyurea, to minimize the risk of leukostasis related-complications; hydroxyurea is permitted up to 24 hours prior to starting azacitidine~* Men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; men should not father a child while participating in this study~* Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* Patients who have had chemotherapy, radiotherapy or investigational agents within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier~* Patients who have received prior radiation greater than 3000 cGy to marrow producing areas~* Patients may not be receiving any other investigational agents~* Patients with active central nervous system (CNS) leukemia; prior CNS leukemia is permitted provided the cerebrospinal fluid has cleared and there is no other evidence of active CNS leukemia~* Prior therapy for AML with decitabine, azacitidine, mitoxantrone, or etoposide~* Prior therapy with azacitidine or decitabine for pre-existing MDS~* History of allergic reactions attributed to decitabine, azacitidine, etoposide, mitoxantrone, or compounds of similar chemical or biologic composition~* Uncontrolled intercurrent illness including, but not limited to, active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Human immunodeficiency virus (HIV)-positive patients with cluster of differentiation (CD) counts less than 500/mm\^3 and/or a history of HIV/acquired immune deficiency syndrome (AIDS)-related complications will be excluded from the study

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (azacitidine, mitoxantrone hydrochloride, etoposide) (Type: EXPERIMENTAL): Patients receive induction therapy comprising azacitidine SC QD on days 1-7, mitoxantrone hydrochloride IV over 30 minutes, and etoposide IV over 1 hour on days 4-8. Patients may receive up to 2 additional courses of the same treatment as re-induction or consolidation therapy beginning 35-60 days from the start of the previous course.

Based on this trial design, predict the completion outcome and termination type (if applicable).